GMAB vs INCY

For growth investors, Genmab A/S (GMAB) is the stronger pick with 30.

7% revenue growth year-over-year, versus 21. 2% for Incyte Corporation (INCY). Genmab A/S (GMAB) offers the better valuation at 14. 6x trailing P/E (24. 0x forward), making it the more compelling value choice. Analysts rate Genmab A/S (GMAB) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Genmab A/S (GMAB) is the cheapest at 14.

6x versus Incyte Corporation at 15. 6x. On forward P/E, Incyte Corporation is actually cheaper at 13. 3x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Incyte Corporation (INCY) delivered a total return of +21.

3%, compared to -25. 1% for Genmab A/S (GMAB). Over 10 years, the gap is even starker: GMAB returned +90. 4% versus INCY's +41. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Incyte Corporation (INCY) is the lower-risk stock at 0.

87β versus Genmab A/S's 0. 94β — meaning GMAB is approximately 7% more volatile than INCY relative to the S&P 500. On balance sheet safety, Incyte Corporation (INCY) carries a lower debt/equity ratio of 1% versus 3% for Genmab A/S — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Genmab A/S (GMAB) is pulling ahead at 30.

7% versus 21. 2% for Incyte Corporation (INCY). On earnings-per-share growth, the picture is similar: Incyte Corporation grew EPS 41. 7% year-over-year, compared to 83. 9% for Genmab A/S. Over a 3-year CAGR, GMAB leads at 36. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Genmab A/S (GMAB) is the more profitable company, earning 36.

4% net margin versus 25. 0% for Incyte Corporation — meaning it keeps 36. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMAB leads at 31. 1% versus 26. 1% for INCY. At the gross margin level — before operating expenses — GMAB leads at 95. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Incyte Corporation (INCY) trades at 13.

3x forward P/E versus 24. 0x for Genmab A/S — 10. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GMAB: 43. 1% to $39. 90.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Incyte Corporation (INCY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

87)). Both have compounded well over 10 years (INCY: +41. 3%, GMAB: +90. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.